Compare Merck & Co., Inc. (MRK) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nerdwallet Inc — how do they compare? Merck & Co., Inc. trades at $145.34 (market cap $351.28B), while Nerdwallet Inc trades at $9.83 (market cap $625.17M). The key difference: Merck & Co., Inc. is far larger — about 561.9× Nerdwallet Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Nerdwallet Inc for 45 Days on average.
| MRK | NRDS | |
|---|---|---|
Market Cap | $351.28B | $625.17M |
Volume | 7,969,665 | 1,321,316 |
Sector | Health | Media |
52-Week High | $156.43 | $15.93 |
52-Week Low | $82.49 | $7.58 |
Typical Hold Time | 98 Days | 45 Days |
Enterprise Value | $398.04B | $539.47M |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
NerdWallet (NRDS) trades at $10.03, up 10.4% in the last session, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with improving fundamentals - revenue grew from $539M in 2022 to $837M in 2025, with net income turning positive since 2024. Recent news highlights the company's Financial Resilience Index publications and Q2 2026 results showing 6% revenue growth despite search pressure in some product categories.
The outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and projecting 27.9% upside potential. Key risks include organic search volatility and competitive pressures, but strong cash flow generation and attractive valuation multiples (P/E 10.87, P/S 0.81) support the bullish case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
